AstraZeneca: trial results for rhinosinusitis
(CercleFinance.com) - Results from the OSTRO phase III trial have showed that AstraZeneca Fasenra (benralizumab) compared to placebo demonstrated a statistically significant improvement in the nasal polyp size and nasal obstruction in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Fasenra demonstrated a statistically significant improvement in endoscopic total nasal polyp score (NPS) and nasal blockage score (NBS) compared to placebo.
CRSwNP is an inflammatory disease associated with high levels of eosinophils in the upper respiratory tract, characterised by benign growths, called nasal polyps.
Polyps can cause nasal obstruction and discharge, a reduced or lost sense of smell, sleep disturbance, and other adverse effects.
Copyright (c) 2020 CercleFinance.com. All rights reserved.